Beyond Medical Technologies Inc (DOCT) AI Stock Analysis

• Market Cap: C$6.56M
• Dividend Yield: N/A
• Average Volume (3M): 29.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: N/A
• EPS Growth: -55.56%
• Country: CA
• Employees: N/A
• Sector: Industrials
• Sector Strength: 72
• Industry: Industrial - Pollution & Treatment Controls
• EPS (TTM): <0.01
• Shares Outstanding: 32,793,960
• 10 Day Avg. Volume: 26,926
• 30 Day Avg. Volume: 29,782
• PEG Ratio: 20.13
• Price to Book (P/B): -0.45
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.52
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.21 ▼(-12.08% Downside)
• Action: Reiterated Date: 01/14/26
• Date: Action: Reiterated 01/14/26

The score is held down primarily by weak financial performance—ongoing losses, negative cash flow, and missing revenue since 2022—plus added financing risk from the TTM debt increase. Technicals are also negative with the price below major moving averages and a negative MACD, while valuation offers little support given the loss-driven negative P/E and no dividend.

Positive Factors

Balance sheet recovery

The restoration of positive equity in the TTM period signals improved solvency and a larger asset base. That durable improvement increases the firm's ability to raise capital, negotiate with creditors and suppliers, and provides a steadier financial foundation to pursue operational recovery over the medium term.

Reduced cash burn trend

Material progress in reducing negative FCF indicates management has cut costs or improved operational efficiency. A sustained trend toward breakeven cash generation lowers dependency on external financing and meaningfully improves the odds of reaching positive operating cash flow within months to a few quarters.

Structural industry tailwinds

Operating in pollution and treatment controls offers long-term demand driven by regulation, environmental standards and corporate ESG adoption. These structural tailwinds create recurring market opportunities and provide a durable backdrop for revenue recovery if the company can reestablish product-market fit and commercial execution.

Negative Factors

No reported revenue since 2022

A multi-year absence of revenue eliminates visibility into demand and product-market fit, preventing organic cash generation. Without durable revenue, the business model remains unproven, forcing reliance on financing and raising the risk of dilution, restructuring, or failure unless revenues recur.

Persistent operating losses

Deep, sustained losses erode capital and limit reinvestment capacity. Continued negative profitability reduces strategic options, undermines credibility with partners and lenders, and means the company must execute material operational or commercial improvements to achieve sustainable margins.

Sharp rise in debt and leverage

A rapid increase in debt raises leverage and refinancing risk at a time when operating cash flow is negative and revenue is absent. Higher fixed obligations constrain flexibility, increase interest and default risk, and may force dilutive equity issuance or asset sales, impairing long-term recovery prospects.

Beyond Medical Technologies Inc Business Overview & Revenue Model

Company Description

Republic Technologies, Inc. engages in the manufacturing of personal protective equipment. It operates through the following segments: Corporate, PPE Sector, and Waste Treatment. The company was founded by Bharath Bhushan on November 29, 2006 and is headquartered in Vancouver, Canada.

How the Company Makes Money

Beyond Medical Technologies Inc generates revenue through the sale of its proprietary medical devices and technology solutions to healthcare providers, hospitals, and clinics. The company also monetizes its telemedicine platforms through subscription models and partnerships with healthcare institutions. Additionally, Beyond Medical Technologies Inc engages in strategic collaborations with pharmaceutical companies and research institutions to co-develop and license new technologies, contributing to its revenue streams.

Beyond Medical Technologies Inc Financial Statement Overview

Summary

Overall fundamentals are high risk: persistent operating losses (TTM EBIT -1,196,986; net income -1,726,132), consistently negative operating/free cash flow (TTM OCF/FCF about -470k), and no reported revenue from 2022 through TTM. Balance sheet improved to positive equity in TTM (1,881,812) but the sharp rise in debt (TTM 1,266,258) and prior negative equity keep financial quality weak.

Income Statement

Operating performance is weak and volatile. The company generated revenue in 2020–2021 (2021 revenue: 943,425), but revenue is reported as 0 from 2022 through TTM (Trailing-Twelve-Months), limiting visibility into the business model and demand. Profitability is consistently negative: TTM (Trailing-Twelve-Months) EBIT is -1,196,986 and net income is -1,726,132, and 2021 margins were deeply negative (net margin about -268%). Losses narrowed materially in 2024 (net income near breakeven at -285) but widened again in the TTM period, signaling uneven cost control and an incomplete turnaround.

Balance Sheet

The balance sheet shows mixed signals with elevated risk. Equity was negative in 2023–2024 (2024 equity: -620,659), which is a red flag for solvency and financial flexibility, but it improves to positive in TTM (Trailing-Twelve-Months) (equity: 1,881,812) alongside a much larger asset base (assets: 7,141,568). Total debt rises sharply in TTM (Trailing-Twelve-Months) to 1,266,258 (from 60,000 in 2024), increasing leverage and refinancing risk despite the equity recovery. Overall, the recent improvement in equity is a positive, but the rapid step-up in debt and history of negative equity keep balance-sheet quality below average.

Cash Flow

Cash generation remains pressured. Operating cash flow is negative across all periods, including TTM (Trailing-Twelve-Months) at -470,330, implying the business is still consuming cash to operate. Free cash flow is also negative in TTM (Trailing-Twelve-Months) (-470,326), though it is less negative than 2023 (-527,044) and far better than 2020–2022 levels, indicating some progress in reducing cash burn. However, the company still appears dependent on external funding (debt/equity issuance) until operating cash flow turns sustainably positive.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	943.42K	208.66K
Gross Profit	0.00	0.00	0.00	0.00	-250.00K	-73.24K
EBITDA	-1.46M	-365.88K	-37.96K	-773.00K	-1.34M	-6.35M
Net Income	-1.73M	-285.00	-596.00K	-1.40M	-2.91M	-6.52M
Balance Sheet
Total Assets	7.14M	13.80K	95.64K	608.18K	1.95M	1.84M
Cash, Cash Equivalents and Short-Term Investments	7.06M	13.22K	64.14K	536.75K	1.43M	624.21K
Total Debt	1.27M	60.00K	30.00K	0.00	85.09K	165.01K
Total Liabilities	5.26M	634.46K	430.35K	346.94K	413.28K	361.85K
Stockholders Equity	1.88M	-620.66K	-334.72K	261.25K	1.54M	1.48M
Cash Flow
Free Cash Flow	-470.33K	-109.77K	-527.04K	-894.01K	-1.47M	-2.07M
Operating Cash Flow	-470.33K	-109.77K	-527.04K	-894.01K	-1.40M	-1.83M
Investing Cash Flow	-2.97M	0.00	0.00	0.00	-467.99K	-260.27K
Financing Cash Flow	5.53M	30.00K	30.00K	0.00	2.67M	-65.96K

Beyond Medical Technologies Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DOCT, the sentiment is Negative. The current price of 0.24 is above the 20-day moving average (MA) of 0.21, above the 50-day MA of 0.23, and below the 200-day MA of 0.44, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 40.45 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DOCT.

Beyond Medical Technologies Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
DOCT	42 Neutral	C$6.56M	-2.55	-319.50%	―	―	-55.56%
ATMO	42 Neutral	C$475.25K	-1.47	―	―	―	19.70%
APL	40 Underperform	C$3.53M	-37.50	-1.36%	―	―	-144.44%

Beyond Medical Technologies Inc Corporate Events

Republic Technologies Expands ETH Holdings and Infrastructure

Republic Technologies Inc. has significantly expanded its ETH holdings, now totaling 1,570.60 ETH, and has seen a 23% appreciation in value. This expansion is part of their strategy to strengthen their infrastructure and enhance their capacity for generating attestations that safeguard data integrity. The company employs ‘Synthetic Mining’ strategies to acquire ETH at lower prices and generate additional revenue without issuing new equity. These efforts, alongside their recent OTCQB listing and secured convertible note facility, position Republic to scale its validator operations and increase attestation output, aligning with their mission to leverage Ethereum technology for data integrity.

Republic Technologies Secures Initial US$10 Million from Convertible Note Facility

Republic Technologies Inc. has successfully completed the first drawdown of its US$100 million secured convertible note facility, raising US$10 million. The funds will primarily be used to acquire Ethereum to support the company’s validator infrastructure and attestation services. The issuance included 27,904,000 common share purchase warrants, potentially providing an additional US$10 million if fully exercised. This move strengthens Republic’s position in the Ethereum infrastructure sector, with no new control person created and necessary shareholder approvals obtained.

Republic Technologies Expands U.S. Market Presence with OTCQB Listing

Republic Technologies Inc. has announced its listing on the OTCQB Venture Market in the United States under the ticker symbol DOCKF, with its shares now eligible for electronic clearing through the Depository Trust Company. This move is part of the company’s strategy to increase visibility and participation among U.S. investors, enhancing its reach to a broader pool of retail and institutional investors. The company’s business model, which leverages Ethereum’s Proof-of-Stake upgrade, allows it to operate in an asset-light manner, minimizing overhead and reducing operational risks. This strategic positioning amid market volatility aims to generate diversified revenue streams while maintaining risk-disciplined exposure to the technological ecosystem.

Republic Technologies Secures $100M Convertible Note Facility to Boost Ethereum Infrastructure

Republic Technologies Inc. has entered into a definitive investment agreement for a secured convertible note facility worth up to US$100 million with an institutional investor. The financing will support the company’s blockchain-based attestation platform and validator infrastructure, aligning with its strategy to accumulate Ethereum (ETH) and enhance its network infrastructure. The facility includes a 24-month term with a 0% interest rate and a 10% original issue discount, secured by ETH collateral. The first drawdown of US$10 million is expected to close by December 5, 2025, with further drawdowns and top-up tranches available under certain conditions. The company plans to allocate 90% of the proceeds to acquire ETH, with the remainder for general working capital.